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ABSTRACT
Introduction: Sentinel lymph node biopsy (SLNB) is an important adjunct in the staging of
patients with melanoma. Preoperative lymphoscintigraphy (LS) with radiolabeled isotopes is
essential to localize sentinel nodes for removal. Our study compared the effectiveness of
Lymphoseekto standard sulfur colloids (SC) in patients with melanoma undergoing SLNB.
Methods: We queried our IRB-approved melanoma database to identify 370 consecutive
patients who underwent SLNB from 2012-2016 with at least one year of follow up. There were
185 patients in each group. Data points included characteristics of the primary melanoma
lymphoscintigraphy, and SLNB. Student’s t-test and Chi-Square were used to analyze the data
with a p-value of <0.05 being considered significant.
Results: Patients were equally matched in regard to age, sex, and primary characteristics of their
melanoma. In comparison to SC, Lymphoseekrequired lower radiation dosages (p<0.001),
shorter mapping times (p=0.008), and decreased number of sentinel nodes removed (p=0.03).
There was no difference in the number of patients with positive nodes (p=0.5). Additionally,
there were no statistical differences between the two radioactive tracers in regard to the number
of patients with false negative SLNB.
Conclusion: Lymphoseekhas the potential to decrease radioactivity and mapping time in
patients who need SLNB. With a decrease in the number of nodes removed without loss of
sensitivity, there is a potential to avoid unnecessary node removal and thus complications such as
lymphedema. Longer follow-up will help to determine if there is any increase in false negative
rates despite fewer nodes removed.

Key Words: Melanoma, sentinel lymph node, lymphoscintigraphy, radiocolloids
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INTRODUCTION
Sentinel lymph node biopsy (SLN) biopsy has been established as the standard of care for
staging patients with intermediate-thickness (>1mm) cutaneous melanoma. SLN mapping allows
for the identification of lymph nodes draining the lymphatic pathway from the primary tumor.
Typically, two types of agents are used in this mapping—vital blue dyes such as Lymphazurin
which stain the sentinel nodes blue and radiopharmaceuticals which are tracked with
lymphoscintigraphy. The most commonly used radiopharmaceuticals used in the United States
are large molecular weight radiocolloids, such as 99mTc-labeled sulfur colloid (SC). Due to their
large size, radiocolloids are slowly cleared from the injection site resulting in delayed migration
to the lymphatics and this retention may mask regionally located lymph nodes in some instances.
Radiocolloids can also be associated with notable injection site pain.
Tc-tilmanocept (Lymphoseek) is a novel molecular agent which accumulates in

99m

lymphatic tissue by binding mannose receptors residing on the surface of lymphatic
reticuloendothelial cells (1). It was approved by the Food and Drug Administration for lymphatic
mapping in solid tumors in 2014 (1) and is being used more now in patients with breast cancer,
melanoma, and squamous cell carcinoma of the head and neck. The novel radiotracer
Lymphoseek provides advantages over blue dyes and radiocolloids due to its structure.
Lymphoseek displays rapid uptake and retention within SLNs, and its small diameter permits
rapid injection site clearance. Compared to radiocolloids, Lymphoseek is also associated with
decreased injection site pain (2). In this study, we sought to compare the efficacy of
Lymphoseek to the standard radiocolloids used during SLNB procedures at our institution since
we began using Lymphoseekin July of 2014.
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METHODS
Following Thomas Jefferson University Institutional Review Board approval with a
waiver of informed consent, we performed a retrospective chart review and identified
consecutive patients who underwent SLNB between 2012 and 2016 and had at least one year of
follow up. The following data points were collected. For the primary tumor, we evaluated the
primary site, Breslow thickness, and whether the tumor was ulcerated. For the
lymphoscintigraphy, we reviewed reports and films to identify the dosage of radiotracer, the
mapping time, and the number of hot spots identified in each patient. Finally, for the SLNB, we
recorded the number of sentinel nodes removed and the number of positive sentinel nodes.
SLN Mapping and Biopsy
All of the procedures were performed by two authors (JCK and ACB). Sentinel lymph
node biopsies were performed using the following technique. Patients received intradermal
injection of 4 doses of ~150 microcuries 99mTc sulfur colloid or 4 doses of ~125 microcuries of
Lymphoseekon the morning of surgery followed by lymphatic mapping to locate the lymph
node drainage basin. All patients underwent full body scanning after injection with SC or
Lymphoseek. To determine the mapping time, we reviewed all images and reports to identify
how long patients were mapped as well as when the last radiograph was taken (Figure 1). We did
not evaluate when the first node was imaged. Intraoperatively, patients received intradermal
injection of either 1 ml of isosulfan blue (LymphazurinTM 1%; Tyco International, Exeter, NH)
or 1 ml of methylene blue at the site of the primary tumor. This was followed by a brief massage
of the overlying skin to enhance lymphatic drainage of the injected dye. Radioactivity of the
labeled lymph nodes was measured during surgery using a handheld gamma probe. SLN were
defined as those containing blue dye, those with the highest counter on the gamma probe, or any

5
node that had greater than 10% radioactivity as compared to the hottest node. All SLN were
removed and sent for pathological evaluation.
Pathologic evaluation of lymph nodes
All identifiable lymph nodes were entirely submitted. Two deeper hematoxylin and eosin
(H&E) stained sections were prepared from the formalin-fixed, paraffin embedded blocks, about
8-12 microns between each level, and depending on size of lymph node, multiple sections were
placed on each slide. If no tumor is seen on initial routine sections, then a panel of
immunohistochemical antibodies was analyzed including any one or more of the following
antibodies: S-100, Melan A, HMB-45, and more recently SOX-10.
Patients were considered to have a false-negative sentinel lymph node biopsy (FNSLNB) if they developed LN recurrence in a LN basin where a sentinel node biopsy was
previously performed or in a basin where mapping could theoretically occur. For example, in a
patient with a melanoma on the mid-lateral trunk that mapped to the axilla but then recurred in
the groin on the same side, we considered that to be a FN-SLNB. We did not consider patients
who developed satellite, in-transit, and/or systemic metastases at the same time as a regional LN
recurrence to have a FN-SLNB because of the possibility that these metastases could have led to
the regional LN involvement.
Statistical Analysis
To evaluate the differences between the SC and Lymphoseekgroup t-tests were
performed with a p-value less than or equal to 0.05 being considered significant. Additionally, a
chi-squared test was used to evaluate the rate of false negative between the two groups.
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RESULTS
Between 2012 and 2016, we identified a total of 370 patients who underwent sentinel LN
biopsy in this cohort with 185 patients in each group. Characteristics of the entire population are
demonstrated in Table 1. When comparing the sulfur colloid (SC) group and the
Lymphoseekgroup, the average patient age was 59.6 and 60.9 and in both groups, there were
more males than females (60.5% and 56.2%), respectively. The distribution of primary
melanoma sites was fairly equal with melanomas of the trunk, extremity, and head and neck
having equal representation in both groups. There were two and one patients respectively with
subungal primary sites. The average Breslow thickness was similar with 2.9 (range=0.3-37mm)
and 2.6 (range=0.35-45mm), respectively. The number of melanomas with ulceration present
was also similar between the two groups. The median follow-up time was significantly longer in
the SC group which was treated in the earlier years of this study (Table 1).
Being that the two groups were matched in regards to demographic characteristics, we
sought to evaluate differences between the groups regarding sentinel lymph nodes and
lymphoscintigraphy procedures. (Table 2). All patients underwent full body scanning after
injection with SC or Lymphoseek. Images and reports were all reviewed. The dose of
radioactivity used for injection was significantly lower in the Lymphoseekgroup (503 vs. 580
µCi, p<0.0001). The average mapping was significantly lower in the Lymphoseekgroup (31 vs.
34 minutes, p<0.008). We also evaluated differences in mapping time by determining the number
of patients who had mapping for longer than 30 minutes. In the SC group, the vast majority of
patients (n=129, 70%) had mapping times of 30 minutes or greater compared to 109 (59%) in the
Lymphoseekgroup; this difference was significantly different as well (p=0.04).
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Additionally, we attempted to identify the number of hot spots per lymph node drainage
basin. There was no statistical difference between the two groups in this regard (2.3 vs. 2.4,
p=0.1, Table 2). There were four patients in the SC group and six patients in the
Lymphoseekgroup who did not have any lymph nodes or hot spots identified on mapping
(p=0.75). In all of these patients, we were able to identify sentinel nodes with use of the
Neoprobe and blue dye. There was no specific pattern regarding the primary sites for these
mapping failures (two chest, one arm, one foot for SC group; three arms, one neck, one chest,
and an abdominal wall for the Lymphoseekgroup)
We found that the average total number of sentinel nodes removed per patient was
higher in the SC group compared to Lymphoseek (2.9 vs 2.5). While this was statistically
significant (p=0.03), the clinical significance of this is difficult to determine. If we look at the
number of patients with more than 5 SLNs removed, there is a non-significant difference
between SC (n=25) and Lymphoseek (n=17). There were 28 patients with positive sentinel
lymph nodes (15%) in the SC group 23 (12%) in the Lymphoseekgroup which was not
significantly different (p=0.5). Finally, we looked back to determine whether there was any
differences in rates of recurrence in the mapped basin for patients with a negative sentinel lymph
node. If we see a difference in this false negative rate, it could indicate some compromise in the
integrity of the mapping. Here we found that the false-negative SLNB rates were equal between
the two cohorts ((1.6%) vs. (1.0%), p=1.0).
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DISCUSSION
The results from this study indicate that Lymphoseek (99Tc-tilmanocept) is able to
identify sentinel nodes in patients undergoing lymphoscintigraphy for melanoma in a shorter
amount of time and with less radioactivity than patients mapped with 9Tc-Sulfur Colloid.
Additionally, with fewer sentinel lymph nodes removed, there is theoretically a decreased
likelihood of lymphedema; with short-term follow-up, there is also no decrement in sensitivity
with equal number of false negative cases. The number of positive nodes removed per patient
was not different, and there was not a significant difference between the percentage of patients
with positive nodes.
Despite there not being a difference in the average number of hot spots per basin seen on
lymphoscintigraphy, we did find a significant difference in the average number of SLNs
removed. This may be explained by Lymphoseek’s specificity for CD206 which allows it to stay
bound to the first lymph node and not have downstream migration. With fewer secondary nodes
taking up the technetium, theoretically, there should be fewer nodes removed. We acknowledge
that there is probably not a clinical significant difference between 2.9 and 2.5 nodes. However, it
is possible that if you extrapolate this difference out over thousands of patients, this could
become a more meaningful clinical difference. The same is true regarding whether this may
possibly contribute to the likelihood of lymphedema. It is interesting to note that there was not a
significant difference in the number of hot spots seen on lymphoscintigraphy between the
groups, yet there was a difference in the number of nodes removed. It is possible that there were
smaller, secondary sentinel nodes that took up the technetium sulfur colloid that were removed at
the time of the sentinel node biopsy which led to the increase in the total number of nodes
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removed. In the end, because this is a retrospective study, we do not have a good explanation for
this finding and acknowledge that it is a limitation of this study.
99

Tc-tilmanocept is a novel radiopharmaceutical which accumulates in lymphatic tissue

by selectively targeting and binding to CD206 receptors on the surface of macrophages and
dendritic cells; these are found in high concentrations in lymph nodes (1). The mannose residue
on the tilmanocept serves as a ligand for the CD206 receptor. Furthermore, targeted receptor
binding limits its migration into distal lymph nodes (3). The average diameter of the 99Tctilmanocept molecule is 7nm—this small size allows for rapid lymphatic uptake (1). On the other
hand, filtered 99Tc-SC particles (which is what we and most investigators in the US use) are
between 100 and 200nm (1).
The FDA approval of Lymphoseekfor the use in lymphatic mapping for solid tumors
followed several clinical trials which demonstrated superior performance over filtered SC.
Baker et al performed a study comparing mapping with tilmanocept and blue dye versus SC with
blue dye in breast cancer patients (4). They found that fewer SLNs were removed in the
tilmanocept patients (p<0.0001) which is similar to what we found in our study. Two nonrandomized phase III trials compared tilmanocept with blue dye for identification of SLN in
melanoma patients. In these studies, tilmanocept identified 232 of 235 blue nodes (98.7%
concordance); tilmanocept detected 364 nodes only 232 of which were detected by blue dye
(64% reverse concordance) (5). Additionally, in this study, tilmanocept identified more positive
nodes than blue dye. Similar results were seen in a phase III study in patients with breast cancer
(6). Finally, a multi-center phase III trial in cutaneous or intraoral squamous cell carcinoma of
the head and neck demonstrated a high overall accuracy and low false-negative rate for
Lymphoseek (7).
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One of the important differences that exist between SC and Lymphoseekis the
differences in injection site pain. Because of the retrospective nature of this trial, we were not
able to effectively evaluate that parameter. However, a recent randomized trial in breast cancer
patients showed a significant decrease in pain scores for patients injected with
Lymphoseekcompared to SC (2). In this study, 52 patients were randomized between the two
radiocolloids. The investigators found that at one, two, and three minutes post injection, the
Lymphoseekpatients had significantly lower pain scores using the visual analog scale (2). Other
investigators have attempted to ameliorate the pain associated with SC injection with addition of
lidocaine and bicarbonate to SC (8), separate lidocaine injection (9), or topical anesthetic cream
(10) with mixed success.
It is not completely clear why SC induces significantly more pain at the injection site. It
was thought that this may be due to the pH of the agents. However, in the Stojadinovic study,
there was no change in pain scores when the pH of SC was altered by mixing with bicarbonate
(8). One possible reason for the increased pain could be the particle size. The small size of
Lymphoseekparticles allows for their rapid transit away from the injection site. Additionally, it
is postulated that the larger size of the SC particles may increase the stretch on the nocioceptive
pain receptors in the dermis leading to patients experiencing a more intense pain (2).
In regards to shorter mapping times, even though we found a significant difference in
mapping times, in reality, there was only a three minute difference. In previously unpublished
work from our institution (presented at the 2015 meeting of the Radiologic Society of North
America), we found that all 34 patients evaluated had reached the maximum number of
identified lymph nodes at 20 minutes as opposed to the 40-45 minutes that most patients with SC
were undergoing imaged. Additionally, when we look at our data set, in the SC group, the vast
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majority of patients had mapping times of 30 minutes or greater compared to the
Lymphoseekgroup; this difference was significantly different as well (p=0.04). It is our hope
that now that we have established our experience with Lymphoseek that we can cut short our
mapping times at a maximum of 20 minutes. This has the ability to move patients through the
system faster with fewer operating room delays and greater patient satisfaction. It is not our
routine practice to have patients undergo lymphoscintigraphy the day before their operation
because in our academic referral practice, the majority of our patients live a considerable
distance away.
We would like to acknowledge several limitations of our study. First of all, this is a nonrandomized study which relied on a consecutive series of patients from before and after the time
that our institution switched over to using Lymphoseekexclusively. Secondly, our follow-up
times for the Lymphoseekpatients are significantly shorter (25.2 versus 5.4 months) because
these patients were only operated on in the last 3 years. Even though our false-negative rate was
no different between the two groups, this may change with longer follow-up in the
Lymphoseekgroup. Finally, our mapping times are pulled from radiology reports. We did not
go back to prospectively evaluate every lymphoscintigraphy study to determine whether there
was additional benefit in the number of nodes identified with longer mapping times. We did not
perform a formal cost analysis in this study. The cost of Lymphoseekis significantly more than
sulfur colloid ($522.00 vs. $74.18). Our hope is that with more experience we will be able to
have patients go through the Nuclear Medicine Department faster with less pain, and this will
justify the increased cost.
In conclusion, it is felt that the ideal lymph node mapping agent should exhibit rapid
clearance from the injection site, rapid uptake within the first draining lymph node as well as low
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uptake by the remaining lymph nodes. It should also have a low radiation dose and absorption
(11). This study, albeit a small non-randomized one, has demonstrated that
Lymphoseekdemonstrates these characteristics. Our institution is using this agent for mapping
in all melanoma, Merkel Cell carcinoma, and most breast cancer patients.
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TABLES AND FIGURES
Table 1. Patient Demographics and Summary Statistics

N (%)
Age, years

Sulfur Colloid
185 (50%)
59.6 (18-89)

Lymphoseek
185 (50%)
60.9 (24-87)

(average, range)
Sex
Male

112

104

Female

72

81

1.5:1
2.9

1.3:1
2.6

48
135

43
130

28
71
20
27
11
12
16

22
75
33
24
8
14
9

20
85
87
2
25.2

22
76
86
1
5.4

(Male: Female)
Breslow, mm (average)
Presence of Ulceration
Ulcerated
Non-ulcerated
AJCC Stage Group
Ia
Ib
IIa
IIb
IIc
IIIa
IIIb
Primary Site
Head/neck
Trunck
Extremity
Subungal
Median Follow-up Time
(months)
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Table 2. Mapping and SLN Biopsy Characteristics
Sulfur Colloid
(n=185, 50%)
580.5

Lymphoseek
(n=185, 50%)
503

p value

Average Mapping

33.6

30.7

0.008

Time, minutes

(5-65)

(10-60)

129 (70%)

109 (59%)

0.04

2.3

2.4

0.10

2.9

2.5

0.035

28 (15.1%)

23 (12.4%)

0.5

3

2

P=1.0

Average Dosage,

<0.0001

uCi

(range)
# of patients with
mapping > 30 min
Average number of
hot spots/basin
Average total
number SLN
removed
Number patient
with + sentinel
nodes
Number of False
Negatives

